Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for GLAXO
Revenue projections for GLAXO

GLAXO's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 40.475914
debtToEquity 0.510000
earningsGrowth 0.125000
revenueGrowth -0.012000
grossMargins 0.623960
operatingMargins 0.292710
trailingEps 56.170000
forwardEps 57.900000

GLAXO's positive gross and operating margins reflect its profitability and efficiency. These metrics demonstrate the company's ability to manage costs effectively while generating strong revenue, highlighting its solid financial health and operational effectiveness.
GLAXO's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that GLAXO is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.

Price projections:

Price projections for GLAXO
Price projections for GLAXO

The price of GLAXO has regularly been close to the lower end of projections, suggesting that it might be struggling to meet market expectations. This trend raises questions about the company's future performance.

Recommendation changes over time:

Recommendations trend for GLAXO
Recommendations trend for GLAXO


GLAXO has received a mixed assessment from analysts, with no definitive buy or sell recommendations. Investors might find it prudent to take a broader approach, considering various market factors, as the analysts' lack of clarity leaves room for different interpretations.